EXHIBIT 99



Bioject Medical Technologies Inc.
Cecelia C. Heer
Investor Relations Manager
908-470-2800, x 5103
cheer@bioject.com



                          BIOJECT MEDICAL TECHNOLOGIES
                       ADOPTS SHAREHOLDER RIGHTS AGREEMENT


        Bedminster, NJ, July 2, 2002 - Bioject Medical Technologies Inc.
(Nasdaq: BJCT), a leading developer of needle-free drug delivery systems,
announced today that its board of directors has adopted a shareholder rights
agreement. To implement the agreement, Bioject will issue a dividend of one
right for each share of its common stock held by shareholders of record as of
the close of business on July 19, 2002. The rights will initially attach to and
trade with the certificates representing outstanding common stock. No separate
certificates will be issued.

         The purpose of the rights agreement is to obtain maximum value for
shareholders in the event of an unsolicited acquisition attempt. The agreement
was not adopted in response to any efforts to acquire the Company and the
Company is not aware of any such efforts.

        Each right will initially entitle shareholders to purchase a fractional
share of the company's preferred stock for $50.00. However, the rights are not
immediately exercisable and will become exercisable only if certain events
related to an unsolicited acquisition attempt occur. For example, unless earlier
redeemed for $0.001 per right, when a person or group acquires 15% or more of
Bioject's common stock, all rights holders (except the person or group who
acquired the triggering amount of shares) will be able to exercise their rights
for shares of Bioject having a value of twice the right's then-current exercise
price. Bioject will send a letter to its shareholders as of the record date that
describes further details of the agreement.


        ABOUT BIOJECT

        Bioject Medical Technologies Inc., based in Bedminster, New Jersey, and
Portland, Oregon, is an innovative developer and manufacturer of needle-free
drug delivery systems. Needle-free injection works by forcing medication at high
speed through a tiny orifice held against the skin. This creates a fine stream
of high-pressure fluid penetrating the skin and depositing medication in the
tissue beneath. The Company is focused on developing mutually beneficial
agreements with leading pharmaceutical and biotechnology companies. Bioject's
partners include Serono and Alkermes.

        This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements involve known and unknown risks, uncertainties and
other factors that may cause the actual results, performance or achievements of
the company, or industry results, to be materially different from any future
results, performance, or achievements expressed or implied by such
forward-looking statements. Readers of this press release are referred to the
Company's filings with the Securities and Exchange Commission, including the
Company's reports on Forms 10-K and Forms 10-Q for further discussions of
factors that could affect future results. Forward-looking statements are based
on the estimates and opinions of management on the date the statements are made.
The Company assumes no obligation to update forward-looking statements if
conditions or management's estimates or opinions should change.

For more information about Bioject, visit www.bioject.com.


                                      # # #